

16-1150. Applicants respectfully request that the amendments and remarks made herein be entered into the record of the instant application.

**IN THE CLAIMS:**

Please amend the claims as set forth below. A marked-up copy of the claim amendments is provided as Exhibit A, and a copy of the pending claims is provided as Exhibit B.

**Please amend claim 34 to read as follows:**

34. (Amended) A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject a non-toxic amount of erythropoietin effective to exert a neuroprotective effect.

**Please add new claims 40 to 63 as follows:**

40. (New) A method for treating cerebral ischemia in a mammal comprising peripherally administering to said mammal an amount of erythropoietin effective to exert a neuroprotective effect without a toxic increase in hemoglobin concentration or hematocrit.

41. (New) The method of Claim 40 wherein said administering is carried out in a vascular fashion.

42. (New) The method of Claim 40 wherein said vascular administration is intravenous.

43. (New) The method of Claim 40, 41, or 42 wherein said erythropoietin is administered for the treatment of stroke.

44. (New) The method of Claim 40, 41, or 42 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

45. (New) The method of Claim 40, 41, or 42 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

46. (New) A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject an amount of erythropoietin effective to exert a neuroprotective effect without a toxic increase in hemoglobin concentration or hematocrit.

47. (New) The method of Claim 46 wherein said administering is carried out in a vascular fashion.

48. (New) The method of Claim 47 wherein said vascular administration is intravenous.

49. (New) The method of Claim 46, 47, or 48 wherein said erythropoietin is administered for the treatment of stroke.

50. (New) The method of Claim 46, 47, or 48 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

51. (New) The method of Claim 46, 47, or 48 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

52. (New) A method for treating cerebral ischemia in a mammal comprising peripherally administering to said mammal an amount of erythropoietin effective to exert a neuroprotective effect without an increase in hematocrit in said mammal.

53. (New) The method of Claim 52 wherein said administering is carried out in a vascular fashion.

54. (New) The method of Claim 53 wherein said vascular administration is intravenous.

55. (New) The method of Claim 52, 53, or 54 wherein said erythropoietin is administered for the treatment of stroke.

56. (New) The method of Claim 52, 53, or 54 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.

57. (New) The method of Claim 52, 53, or 54 wherein said erythropoietin is native erythropoietin, recombinant human erythropoietin or animal erythropoietin or a derivative thereof.

58. (New) A method for treating cerebral ischemia in a human subject comprising peripherally administering to said human subject an amount of erythropoietin effective to exert a neuroprotective effect without an increase in hematocrit in said human subject.

59. (New) The method of Claim 58 wherein said administering is carried out in a vascular fashion.

60. (New) The method of Claim 58 wherein said vascular administration is intravenous.

61. (New) The method of Claim 58, 59, or 60 wherein said erythropoietin is administered for the treatment of stroke.

62. (New) The method of Claim 58, 59, or 60 wherein said erythropoietin is administered at a dosage of 50,000 to 100,000 Units per administration or per day.